Shanghai Fosun Pharmaceutical (Group) Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Shanghai Fosun Pharmaceutical (Group) wird ein jährliches Gewinn- und Umsatzwachstum von 27.6% bzw. 10.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.2% betragen.

Wichtige Informationen

26.9%

Wachstumsrate der Gewinne

27.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.9%
Wachstumsrate der Einnahmen	10.3%
Zukünftige Eigenkapitalrendite	8.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	24 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01

Recent updates

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

May 23

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26

Gewinn- und Umsatzwachstumsprognosen

SHSE:600196 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	53,609	4,595	1,662	5,119	5
12/31/2025	50,502	4,125	1,537	4,384	8
12/31/2024	44,789	3,360	4,645	4,769	7
3/31/2024	40,686	2,009	-1,430	3,458	N/A
12/31/2023	41,400	2,386	-1,922	3,414	N/A
9/30/2023	43,029	3,578	-2,095	3,535	N/A
6/30/2023	43,999	3,972	-2,007	4,229	N/A
3/31/2023	44,437	4,261	-1,858	4,235	N/A
12/31/2022	43,952	3,731	-1,671	4,218	N/A
9/30/2022	43,586	3,600	-1,882	4,066	N/A
6/30/2022	43,406	3,782	-1,252	4,030	N/A
3/31/2022	41,340	4,338	-1,140	4,057	N/A
12/31/2021	39,011	4,729	-1,035	3,938	N/A
9/30/2021	35,253	4,749	-1,525	3,142	N/A
6/30/2021	33,231	4,430	-1,994	2,825	N/A
3/31/2021	32,483	3,933	-1,748	2,934	N/A
12/31/2020	30,307	3,663	-1,857	2,580	N/A
9/30/2020	29,460	3,737	-1,021	3,347	N/A
6/30/2020	28,441	3,520	-592	3,234	N/A
3/31/2020	27,736	3,187	-552	3,197	N/A
12/31/2019	28,585	3,322	-740	3,222	N/A
9/30/2019	28,004	2,677	-449	3,191	N/A
6/30/2019	27,232	2,664	-893	3,122	N/A
3/31/2019	25,929	2,714	-875	2,892	N/A
12/31/2018	24,918	2,708	-225	2,950	N/A
9/30/2018	23,716	2,799	-55	2,945	N/A
6/30/2018	22,040	2,996	287	2,755	N/A
3/31/2018	20,372	3,092	224	2,644	N/A
12/31/2017	18,534	3,124	N/A	2,580	N/A
9/30/2017	16,951	3,047	N/A	2,310	N/A
6/30/2017	16,045	2,993	N/A	2,278	N/A
3/31/2017	15,283	2,908	N/A	2,128	N/A
12/31/2016	14,629	2,805	N/A	2,110	N/A
9/30/2016	14,173	2,745	N/A	1,983	N/A
6/30/2016	13,624	2,657	N/A	1,880	N/A
3/31/2016	13,034	2,557	N/A	1,822	N/A
12/31/2015	12,609	2,459	N/A	1,621	N/A
9/30/2015	12,438	2,429	N/A	1,519	N/A
6/30/2015	12,408	2,398	N/A	1,474	N/A
3/31/2015	12,168	2,234	N/A	1,376	N/A
12/31/2014	12,026	2,113	N/A	1,200	N/A
9/30/2014	11,587	2,207	N/A	1,388	N/A
6/30/2014	11,026	1,987	N/A	1,104	N/A
3/31/2014	10,598	1,646	N/A	942	N/A
12/31/2013	9,996	1,583	N/A	1,012	N/A
9/30/2013	9,024	1,421	N/A	717	N/A
6/30/2013	8,356	1,475	N/A	746	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600196Das prognostizierte Gewinnwachstum (27.6% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: 600196Die Erträge des Unternehmens (27.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (22.7% pro Jahr).

Hohe Wachstumserträge: 600196Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 600196Die Einnahmen des Unternehmens (10.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 600196Die Einnahmen des Unternehmens (10.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600196Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.2%).

Shanghai Fosun Pharmaceutical (Group) Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 12%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 17%

Price target decreased by 13% to CN¥32.65

Price target decreased by 7.0% to CN¥37.41

Consensus forecasts updated

Recent updates

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 23 August 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive and Committee Changes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 26, 2024

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

Consensus EPS estimates fall by 12%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Consensus EPS estimates fall by 17%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Profit margin trend

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) announces an Equity Buyback for CNY 200 million worth of its shares.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that it expects to receive CNY 497.7664 million in funding

Price target decreased by 13% to CN¥32.65

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces National Medical Products Administration Accepts New Drug Application of Cisplatin Injection

Price target decreased by 7.0% to CN¥37.41

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.42 in 2Q 2022)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Approval for Drug Registration of Fosun Kite Biotechnology Co., Ltd

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Annual General Meeting, Jun 28, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Less than half of directors are independent

Consensus forecasts updated

Investor sentiment improved over the past week

Shandong Liancheng Precision Manufacturing Co., Ltd (SZSE:002921) completed the acquisition of 3.9858% stake in Shanghai Shen-li High Tech Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) and Shanghai Fulian Technology Co., Ltd.

Third quarter 2022 earnings: Revenues exceed analyst expectations

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Executive Vice Chairman recently bought CN¥391k worth of stock

Now 20% undervalued after recent price drop

Executive Chairman recently bought CN¥887k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Appoints Wen Deyong as an Executive Director

Price target decreased to CN¥46.32

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥50.41

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommends Final Dividend for 2021, Dispatch of Cheques for the 2021 Final Dividend Payable on H Shares Is 4 July 2022

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥56.55

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to Report Q1, 2022 Results on Apr 26, 2022

Price target decreased to CN¥56.55

Price target decreased to CN¥58.66

Investor sentiment improved over the past week

Insilico Medicine Achieves Its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL

Investor sentiment deteriorated over the past week

Fosun Pharma and Insilico Medicine Announces A Strategic, Ai-Driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

Third quarter 2021 earnings released: EPS CN¥0.42 (vs CN¥0.30 in 3Q 2020)

Tianjin Kingyork Group Co., Ltd. signed the Equity Transfer agreement to acquire an additional 25.0011% stake in Tianjin Pharmaceutical Group Co., Ltd. from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) for CNY 1.4 billion.

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.43 in 2Q 2020)

Director Xiaoliang Xu has joined 4th company board